Skip to main navigation Skip to search Skip to main content

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial

  • Juergen Rech
  • , Koray Tascilar
  • , Melanie Hagen
  • , Arnd Kleyer
  • , Bernhard Manger
  • , Verena Schoenau
  • , Axel J Hueber
  • , Stefan Kleinert
  • , Xenofon Baraliakos
  • , Jürgen Braun
  • , Uta Kiltz
  • , Martin Fleck
  • , Andrea Rubbert-Roth
  • , David M Kofler
  • , Frank Behrens
  • , Martin Feuchtenberger
  • , Michael Zaenker
  • , Reinhard Voll
  • , Nils Venhoff
  • , Jens Thiel
  • Cornelia Glaser, Eugen Feist, Gerd R Burmester, Kirsten Karberg, Johannes Strunk, Juan D Cañete, Ladislav Senolt, Maria Filkova, Esperanza Naredo, Raquel Largo, Gerhard Krönke, Maria Antonietta D'Agostino, Mikkel Østergaard, Georg Schett
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Rheumatology Clinical Practice Erlangen
  • Ruhr University Bochum
  • Asklepios Klinik St. Georg
  • Kantonsspital St Gallen
  • University of Cologne
  • Fraunhofer Institute for Translational Medicine and Pharmacology
  • Med Bayern Ost
  • Immanuel Klinikum Bernau
  • University of Freiburg
  • Charité – Universitätsmedizin Berlin
  • Helios Clinic Vogelsang-Gommern
  • Rheumatology Practice
  • Porz am Rhein Hospital
  • Hematology, Hospital Clínic
  • Charles University
  • Universidad Autónoma de Madrid
  • University of Copenhagen

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)N/A-N/A
JournalThe Lancet
DOIs
Publication statusPublished - 2024

Keywords

  • Abatacept, rheumatoid arthritis, ARIAA,

Cite this